Press Releases
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform
December 11, 2025
New technology combines Pulsed Field Ablation (PFA) and Advanced Radiofrequency Ablation with AtriCure’s EnCompass ® clamp to reduce treatment time for surgical ablation patients MASON, Ohio --(BUSINESS WIRE)--Dec. 11, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical...
AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 18, 2025
MASON, Ohio --(BUSINESS WIRE)--Nov. 18, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025
October 29, 2025
Worldwide revenue of $134.3 million – an increase of 15.8% year over year (15.1% constant currency) Net loss of $0.3 million – an improvement of $7.6 million year over year Adjusted EBITDA of $17.8 million – an increase of $9.9 million year over year Generated $30.1 million of cash in the third...
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial
October 28, 2025
Trial will evaluate the safety and effectiveness of the AtriCure Isolator ® Synergy™ EnCompass ® clamp and AtriClip ® Left Atrial Appendage Exclusion System to reduce the occurrence of new-onset atrial fibrillation in cardiac surgery patients MASON, Ohio --(BUSINESS WIRE)--Oct....
AtriCure to Participate in Upcoming Investor Conferences
October 27, 2025
MASON, Ohio --(BUSINESS WIRE)--Oct. 27, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure to Announce Third Quarter 2025 Financial Results
October 08, 2025
MASON, Ohio --(BUSINESS WIRE)--Oct. 8, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter...
AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation
September 09, 2025
New device expands AtriCure’s market opportunity in post-operative pain management while addressing a significant unmet clinical need MASON, Ohio --(BUSINESS WIRE)--Sep. 9, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation...
AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference
August 20, 2025
MASON, Ohio --(BUSINESS WIRE)--Aug. 20, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025
July 29, 2025
Worldwide revenue of $136.1 million – an increase of 17.1% year over year (16.5% constant currency) Net loss of $6.2 million – an improvement of $1.8 million year over year Adjusted EBITDA of $15.4 million – an increase of $7.6 million year over year Generated $17.9 million of cash in the quarter...
AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference
July 28, 2025
MASON, Ohio --(BUSINESS WIRE)--Jul. 28, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...